Difference between revisions of "Samarium-153 (Quadramet)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http:// | + | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http://quadramet.jazzpharma.com/QuadrametPI.pdf Samarium-153 (Quadramet) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/samarium153.pdf Samarium-153 (Quadramet) package insert (locally hosted backup)]</ref><ref>[http://quadramet.jazzpharma.com/ Quadramet manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Prostate cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | |||
| − | |||
*[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/samarium-sm-153-lexidronam-patient-drug-information Samarium-153 (Quadramet) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, <sup>152</sup>Sm<sub>2</sub>O<sub>3</sub>. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Radioactive agents]] | ||
| + | [[Category:Prostate cancer medications]] | ||
Revision as of 19:59, 16 May 2013
General information
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
Also known as
Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, 152Sm2O3.